Docoh
Loading...

IMGO Imago BioSciences

News

From Benzinga Pro
52 Biggest Movers From Friday
18 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its TapouT performance drink in Walmart stores across Florida metropolitan areas.
12 Health Care Stocks Moving In Friday's Intraday Session
14 Jan 22
Intraday Update, Markets, Movers
30 Stocks Moving In Friday's Mid-Day Session
14 Jan 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5.
50 Biggest Movers From Yesterday
6 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
12 Health Care Stocks Moving In Wednesday's Intraday Session
5 Jan 22
Intraday Update, Markets, Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
28 Dec 21
Intraday Update, Markets, Movers
38 Stocks Moving In Tuesday's Mid-Day Session
21 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday.
Imago BioSciences Presented Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021; Said Bomedemstat Demonstrated Durable Clinical Improvement in Patients With ET Who Failed at Least One Standard Therapy (Usually Hydroxyurea)
12 Dec 21
News, Small Cap, Events
Imago BioSciences, Inc. ("Imago") (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with essential thrombocythemia (ET).
Imago BioSciences Presented Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021; Said Bomedemstat Demonstrated Encouraging and Distinct Clinical Benefit to Patients With Advanced Myelofibrosis
11 Dec 21
News, Small Cap, Events
Imago BioSciences, Inc. ("Imago") (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF).
Mid-Day Market Update: Crude Oil Down 1%; Inspira Technologies Shares Spike Higher
9 Dec 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Thursday, the Dow traded down 0.18% to 35,691.63 while the NASDAQ fell 0.72% to 15,672.75. The S&P also fell, dropping 0.37% to 4,683.86.
60 Biggest Movers From Yesterday
7 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore strategic options to maximize shareholder value, including potential merger or acquisition.
12 Health Care Stocks Moving In Monday's Intraday Session
6 Dec 21
Movers
Gainers
36 Stocks Moving In Monday's Mid-Day Session
6 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
6 Dec 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector recorded weekly losses, reversing course from the previous week's advance.
Imago BioSciences Q3 EPS $(0.44) Up From $(4.23) YoY
10 Nov 21
Earnings, News
Imago BioSciences (NASDAQ:IMGO) reported quarterly losses of $(0.44) per share. This is a 89.6 percent increase over losses of $(4.23) per share from the same period last year.

Press releases

From Benzinga Pro
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
17 Dec 21
Press Releases
BOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021
12 Dec 21
Press Releases
- Expanded Phase 2 data set continues to provide compelling rationale for move to registrational clinical program - - Bomedemstat demonstrated durable clinical improvement in patients with ET who failed at least one
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021
11 Dec 21
Press Releases
- Bomedemstat continues to be generally well-tolerated - - Bomedemstat demonstrated encouraging and distinct clinical benefit to patients with advanced myelofibrosis - - Data highlights rationale for bomedemstat as
Imago BioSciences Appoints Laurie Keating to Board of Directors
18 Nov 21
Press Releases
​Imago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Laurie
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
11 Nov 21
News, Press Releases
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of
Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
10 Nov 21
Earnings, Press Releases
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the treatment of
Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition
4 Nov 21
Press Releases
Imago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced two abstracts have been